Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic neuropathy.

In Phase III MINT trial, Uplizna (inebilizumab) demonstrated significant short-term efficacy and a manageable safety profile ...

Cardio burns more calories per session, while weight training offers sustained metabolic benefits by building lean muscle. HIIT combines both benefits in less time, suggesting a balanced approach ...

Over the last year, 89bio’s stock has been somewhat volatile. Shares climbed past $10 earlier this year, but dropped under $6 ...

A new drug, called orforglipron, can help people with diabetes manage their A1C and weight, according to topline results from ...

Patients with T1D experienced greater reductions in risk for cardiovascular disease with empagliflozin compared with placebo.